Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06928051 · ClinicalTrials.gov registry record · Phase 2
A Study of S-892216 in Participants With COVID-19
A Phase 2 study of COVID-19, sponsored by Shionogi.
- Completed
- Registry status
- Phase 2
- Development phase
- 282
- Enrollment target
- 20
- Study locations
NCT06928051 is a Phase 2 study of COVID-19 that has completed, run by Shionogi. The registered enrollment target is 282 participants, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT06928051, a Phase 2 study of COVID-19, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 282 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to investigate the antiviral effect of S-892216 in participants with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG S-892216
Study Locations (20)
Florida
- Invictus Clinical Research Group LLC - Coconut Creek
- Hope Clinical Trials - Coral Gables
- Advanced Research for Health Improvement LLC - Immokalee
- LCC Medical Research - Miami
- CCM Clinical Research Group - Miami
- Global Health Clinical Trials - Miami
- Continental Clinical Research - Miami
- Entrust Clinical Research - Miami
- Kendall South Medical Center Inc - Miami
- Palm Springs Community Health Center - Miami Lakes
- Quality Research of South Florida - Miami Lakes
- Oceane7 Medical & Research Center, Inc. - Miami Lakes
- Combined Research Orlando Phase I-IV LLC - Orlando
- Global Clinical Professionals - St. Petersburg
Texas
- PanAmerican Clincal Research - Brownsville
- Alina Clinical Trials LLC - Dallas
- Care United Research, LLC - Forney
Arkansas
- Healthstar Research - Hot Springs
Georgia
- Balanced Life Health Care Solutions - Lawrenceville
Virginia
- Clinical Research Partners LLC - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2025-06-06 |
| Est. Completion | 2025-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06928051
The ClinicalTrials.gov registry entry for NCT06928051 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06928051 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, Texas, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06928051 about?
NCT06928051 is a clinical study titled "A Study of S-892216 in Participants With COVID-19". The primary objective of this study is to investigate the antiviral effect of S-892216 in participants with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
What is the current status of trial NCT06928051?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 282 participants. The study started on 2025-06-06. Estimated completion is 2025-09-22.
What conditions does trial NCT06928051 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT06928051?
The interventions under investigation include: Placebo (DRUG), S-892216 (DRUG).
Who is sponsoring clinical trial NCT06928051?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06928051 being conducted?
This trial has 20 study locations across Arkansas, Florida, Georgia, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.